Products - Brain cancers | Topic

Showing 11 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2016
Published:
26 April 2001
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2007
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
DCVax-L for treating glioblastoma [ID836]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Asunercept for treating glioblastoma [1301]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Brain cancers Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 11 products

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

DCVax-L for treating glioblastoma [ID836]

Asunercept for treating glioblastoma [1301]

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

Brain cancers Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 11 products

Guidance programme
1 selected